高级检索
当前位置: 首页 > 详情页

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越:梯队期刊

单位: [1]Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan 430071, Peoples R China [2]China Japan Friendship Hosp, Natl Clin Res Ctr Resp Dis, Beijing 100029, Peoples R China [3]China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing 10029, Peoples R China [4]Leishenshan Hosp Wuhan, Wuhan 430200, Peoples R China [5]Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430071, Peoples R China [6]Henan Univ, Inst Evidence based Med & Knowledge Translat, Kaifeng 475000, Henan, Peoples R China [7]Guizhou Prov Peoples Hosp, Dept Med Imaging, Guiyang 550002, Peoples R China [8]Wuhan Univ, Dept Orthoped, Zhongnan Hosp, Wuhan 430071, Peoples R China [9]Wuhan Univ, Dept Hepatobiliary Surg, Zhongnan Hosp, Wuhan 430071, Peoples R China [10]Sichuan Univ, Natl Clin Res Ctr Geriatr, West China Hosp, Chengdu 610041, Peoples R China [11]Sichuan Univ, Dept Geriatr, West China Hosp, Chengdu 610041, Peoples R China [12]Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan 430071, Peoples R China [13]Chinese Acad Med Sci CAMS, Peking Union Med Coll Hosp PUMCH, Peking Union Med Coll, Dept Clin Lab, Beijing 100730, Peoples R China [14]Lund Univ & Region Skane, Ctr Primary Hlth Care Res, S-25002 Malmo, Sweden [15]Wuhan Univ, Emergency Ctr, Zhongnan Hosp, Wuhan 403371, Peoples R China [16]Wuhan Univ, Dept Allergol, Zhongnan Hosp, Wuhan 430071, Peoples R China [17]Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, Wuhan 43071, Peoples R China [18]Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430060, Peoples R China [19]Shandong Univ, Dept Emergency Med, Qilu Hosp, Jinan 250002, Peoples R China [20]Shandong Univ, Chest Pain Ctr, Qilu Hosp, Jinan 250002, Peoples R China [21]Hubei Univ Med, Suizhou Cent Hosp, Dept Resp & Crit Care Med, Suizhou 441300, Hubei, Peoples R China [22]Second Peoples Hosp Huaihua City, Dept Clin Pharm, Huaihua 418000, Hunan, Peoples R China [23]Anhui Med Univ, Dept Intens Care Unit, Affiliated Hosp 2, Hefei 230601, Peoples R China [24]Zhengzhou Univ Hosp, Dept Internal Med, Zhengzhou 450001, Peoples R China [25]Henan Prov Peoples Hosp, Dept Resp & Crit Care Med, Zhengzhou 450003, Peoples R China [26]Fudan Univ, Dept Infect Dis, Childrens Hosp, Shanghai 201102, Peoples R China [27]Sichuan Univ, West China Hosp 2, Dept Infect Dis, Chengdu 610041, Peoples R China [28]Henan Univ Chinese Med, Dept Cardiol, Zhengzhou 450000, Peoples R China [29]Three Gorges Univ, Renmin Hosp China, Dept Cardiol, Yichang 443000, Hubei, Peoples R China [30]Wuhan Univ, Dept Pediat, Zhongnan Hosp, Wuhan 430071, Peoples R China [31]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China [32]Shandong First Med Univ & Shandong Acad Med Sci, Shandong Prov Hosp, Dept Pharm, Jinan 250021, Peoples R China [33]Nanjing Univ Chinese Med, Lab Integrated Acupuncture & Drugs, Nanjing 210023, Peoples R China [34]Sichuan Univ, West China Hosp, Dept Period Press, Chengdu 610041, Peoples R China [35]Qingdao Univ, Yantai Yuhuangding Hosp, Dept Clin Lab, Yantai 264000, Shandong, Peoples R China [36]Hubei Univ Med, Taihe Hosp, Dept Radiol, Shiyan 442000, Hubei, Peoples R China [37]Peking Univ, Sch Nursing, Beijing 100191, Peoples R China [38]Kaifeng Cent Hosp, Dept Resp & Crit Care Med, Kaifeng 475000, Henan, Peoples R China [39]Beijing Elect Power Hosp, Dept Emergency, Beijing 100073, Peoples R China [40]Cent South Univ, Second Xiangya Hosp, ICU Ctr, Changsha 410008, Peoples R China [41]Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan 430071, Peoples R China [42]Wuhan Univ, Zhongnan Hosp, Dept Haematol, Wuhan 430071, Peoples R China [43]Henan Univ, Henan Med Sch, Coll Nursing & Hlth, Kaifeng 475000, Henan, Peoples R China [44]Shanxi Med Univ, Sch Nursing, Taiyuan 030001, Peoples R China [45]Capital Med Univ, Beijing Youan Hosp, Dept Diagnost Radiol, Beijing 100069, Peoples R China [46]Wuhan Univ, Dept Resp Med, Zhongnan Hosp, Wuhan 430071, Peoples R China [47]McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4L8, Canada [48]Wuhan Univ, Dept Crit Care Med, Renmin Hosp, Wuhan 430060, Peoples R China
出处:
ISSN:

关键词: COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

摘要:
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis and treatment guidelines for clinicians caring for patients are needed. In the early stage, we have issued "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"; now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline. We formed a working group of clinical experts and methodologists. The steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas: chemoprophylaxis, diagnosis, treatments, and discharge management. We searched the literature for direct evidence on the management of COVID-19, and assessed its certainty generated recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Recommendations were either strong or weak, or in the form of ungraded consensus-based statement. Finally, we issued 34 statements. Among them, 6 were strong recommendations for, 14 were weak recommendations for, 3 were weak recommendations against and 11 were ungraded consensus-based statement. They covered topics of chemoprophylaxis (including agents and Traditional Chinese Medicine (TCM) agents), diagnosis (including clinical manifestations, reverse transcription-polymerase chain reaction (RT-PCR), respiratory tract specimens, IgM and IgG antibody tests, chest computed tomography, chest x-ray, and CT features of asymptomatic infections), treatments (including lopinavir-ritonavir, umifenovir, favipiravir, interferon, remdesivir, combination of antiviral drugs, hydroxychloroquine/chloroquine, interleukin-6 inhibitors, interleukin-1 inhibitors, glucocorticoid, qingfei paidu decoction, lianhua qingwen granules/capsules, convalescent plasma, lung transplantation, invasive or noninvasive ventilation, and extracorporeal membrane oxygenation (ECMO)), and discharge management (including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge). We also created two figures of these recommendations for the implementation purpose. We hope these recommendations can help support healthcare workers caring for COVID-19 patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
JCR分区:
出版当年[2018]版:
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan 430071, Peoples R China
通讯作者:
通讯机构: [1]Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan 430071, Peoples R China [4]Leishenshan Hosp Wuhan, Wuhan 430200, Peoples R China [41]Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan 430071, Peoples R China [46]Wuhan Univ, Dept Resp Med, Zhongnan Hosp, Wuhan 430071, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)